8 This study, which took place over a five-year period, surely contributed to the FDAs approval of semaglutide in early 2024 for use in this population, and demonstrated that, in addition to managing diabetes and obesity, GLP1 receptor agonists offer value in reducing cardiovascular event risk
[3] [4] Administered as a once-weekly subcutaneous injection, Wegovy works by mimicking the action of the naturally occurring hormone GLP-1
In particular, information on the genotype-phenotype characterization of MertS and its characteristics is fragmented
533 CVDs CVDs remain a leading cause of mortality worldwide and pose a severe public health challenge
Gia Eapen, MD, elaborates, It works by raising brain chemicals like norepinephrine and dopamine, which help control hunger signals and food cravings